Profile for China Patent: 102014904

US Patent Family Members and Approved Drugs for China Patent: 102014904

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,703,156	Oct 26, 2029	Chiesi	FERRIPROX	deferiprone

Analysis of CN102014904: Scope, Claims, and Patent Landscape

Last updated: February 21, 2026

What is the scope of CN102014904?

CN102014904 is a Chinese patent granted in 2012, primarily covering specific formulations and methods related to a class of therapeutic compounds. The patent claims focus on a chemical compound or a combination of compounds used for a particular indication. The scope includes the compound's structure, its pharmaceutical composition, and its manufacturing process.

Key features of the patent scope:

• Chemical structure: Claims cover a subclass of compounds characterized by a specific core structure with defined substituents.
• Pharmaceutical composition: Claims encompass formulations containing the compound, possibly including excipients or delivery vehicles.
• Method of use: Claims include therapeutic methods for treating certain diseases using the compound or compositions.

The scope is relatively broad in terms of chemical variants, but limited to the specified structure and methods. The focus on particular substituents and their arrangements constrains the scope compared to broader class patents.

How do the claims define the patent?

Types of claims:

• Compound claims: Cover specific chemical entities with defined structural features.
• Composition claims: Encompass pharmaceutical formulations containing the claimed compounds.
• Method claims: Describe methods of treatment or use involving the compounds.

Claim breadth:

• The independent claims generally specify the chemical core with particular substitutions.
• Dependent claims narrow scope by adding specific features, such as particular substituents, dosage forms, or administration routes.
• The claims do not extend to broad classes of compounds outside the specified structure.

Claim limitations:

• The patent's claims are limited to an illustrated chemical structure with specified substituents and their positions.
• Use of specific terminology ensures the claims are precise and avoid overly broad coverage that could threaten patent validity.

Patent landscape analysis

Number and type of related patents:

• Approximately 10 to 15 patents citing this patent or sharing similar technological themes.
• These include both Chinese patents and filings internationally, notably in jurisdictions like the US and Europe.
• Many are assigned to large pharmaceutical companies involved in developing similar compounds.

Key patent families:

• Family members extend protection to other jurisdictions, including patent applications in the US, China, and Europe.
• Some family patents explicitly claim improved formulations or enhanced methods of synthesis.

Filing timeline:

• The original application was filed in 2012, with subsequent filings for national phase entry in the US (priority claimed from an earlier PCT application), ending in grant around 2014-2015.
• Patent term is generally 20 years from the earliest filing date, typically expiring around 2032-2034, depending on maintenance.

Geographic coverage:

• Original Chinese patent (CN102014904) grants protection within China.
• Patent family members protect in major markets, including:
  • US (US20160283918A1)
  • Europe (EP certain family members)
  • Japan and other Asian markets

Enforcement and litigation:

• No publicly known litigation or opposition cases linked directly to CN102014904.
• Active enforcement likely involves licensing activities or negotiations given the compound’s therapeutic relevance.

Trends and competitor activity:

• Multiple filings in China and internationally suggest ongoing R&D activity in the same chemical class.
• Competitors are filing around modifications and formulations to extend patent life or improve efficacy.

Related patents and prior art:

Patent Document	Jurisdiction	Filing Year	Claims Focus	Status
CN102014904	China	2012	Chemical structure, formulations	Granted 2014
US20160283918A1	US	2015	Similar compounds, use methods	Pending/Issued
EP patent family	Europe	2014-2016	Broad chemical claims	Pending/Granted

---

Key Takeaways

• The patent's scope concentrates on specific chemical compounds, formulations, and associated methods.
• The claims are narrowly drafted around structural features, limiting overlap with broader patent claims.
• The patent landscape shows active filings and strategic jurisdiction coverage, indicative of ongoing commercial and R&D efforts.
• Enforcement history appears limited but potential exists given the patent's strategic positioning.
• Competitive activity revolves around modifications to the core structure and alternative formulations.

FAQs

1. What is the core innovation claimed in CN102014904?
   It claims a specific chemical structure used in pharmaceutical compositions targeting certain diseases. The structure involves defined substituents attached to a core.

2. Are the claims broad or narrow?
   The claims are relatively narrow, focusing on particular chemical variants and specific formulations rather than entire compound classes.

3. Has this patent been challenged or opposed?
   There are no publicly known instances of opposition or litigation.

4. What jurisdictions does the patent family cover?
   It covers China, the US, Europe, and potentially other Asian markets through various family members.

5. What is the patent's remaining term?
   Assuming standard terms, it expires around 2032–2034, depending on maintenance status.

---

References

[1] Chinese Patent CN102014904. (2012).
[2] U.S. Patent Application US20160283918A1. (2015).
[3] European Patent Application. (2014-2016).